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Background: Worldwide access to antiretroviral therapy (ART) in low- and middle-income 2 
countries has significantly increased. Although this presents better treatment options for HIV-3 
infected individuals, the challenge of monitoring ART in these settings still remains.  4 
Objective: To investigate efficient and cost-effective criteria for assessing ART failure 5 
among HIV-1-infected children on first-line ART in resource-limited settings. 6 
Study design: Retrospective analysis of 75 HIV-1 vertically-infected Kenyan children with a 7 
follow-up period of 24 months after initiating ART. Plasma viral load, peripheral CD4+T-cell 8 
counts and HIV-1 drug-resistance mutations were monitored biannually. 9 
Results: Plasma viral load (VL) was suppressed to undetectable level or more than 1.5 log10 10 
from baseline levels in 53 (70.7%) children within 24 months. VL in the remaining 22 11 
(29.3%) children was not suppressed significantly. Of the 22 children, 21 were infected with 12 
HIV-1 strains that developed drug-resistance mutations; 9 within 12 months and 12 between 13 
12-24 months. Among the 53 who were successfully treated, VL was suppressed in 33 within 14 
12 months and in 20 between 12-24 months. There was no significant difference in VL at 15 
baseline and the change of CD4+T-cell counts after initiating ART between those treated 16 
successfully and the failure groups.  17 
Conclusion: After initiating ART, children may require longer times to achieve complete 18 
viral suppression. Plasma viral load testing 24 months after initiating ART could be used to 19 
differentiate ART failures among HIV-1 vertically-infected children in resource-limited 20 
settings. Additionally, drug resistance testing, if affordable, would be helpful in identifying 21 
those failing therapy and in choosing second-line regimens. 22 
 23 





Increased availability of antiretroviral therapy (ART) has mitigated HIV-1/AIDS prognoses, 27 
especially in resource-poor settings.1-2 However, many factors such as bad adherence, 28 
treatment interruption, and importantly, the emergence of antiretroviral drug (ARV)-29 
resistance mutations could lead to ART failure.3-13 According to the world health organization 30 
(WHO) treatment guidelines, ART failure is defined as: 1) clinical failure, indicated by new 31 
or recurrent WHO stage 3 and 4 conditions after 24 weeks of ART; 2) immunologic failure, 32 
indicated by CD4+T-cell count of less than 200 cells/mm3 or percentage CD4+T-cell count of 33 
less than 10 for children between two and five years of age and CD4+T-cell count of less than 34 
100 cells/mm3 for children at the age of five years or older, and 3) virologic failure, indicated 35 
by  a persistent plasma viral load (VL) above 5,000 copies/ml after at least 24 weeks of 36 
ART.14 Once a patient is found to be failing ART, change of regimen should be considered, 37 
but choice of second line regimens is limited in resource-poor settings.15-17 Therefore, 38 
monitoring of response to ART is important to determine treatment success. Although plasma 39 
VL is the main index for determining treatment failure in developed countries, it is rare in 40 
resource-poor settings because of high cost. This leaves the clinical and immunologic 41 
markers as the only means of assessing treatment failure.18-21  42 
In children, ART effectively reduces morbidity and hospital admissions, and increases 43 
long-term survival.22 However, monitoring ART is more challenging than in adults. Children 44 
in sub-Saharan Africa seem to be at higher risk for treatment failure, with reported prevalence 45 
of 31.6%, 19.7%, 26%, 23-50% in Tanzania, KwaZulu-Natal (South Africa), Uganda and 46 
Cote d’Ivoire, respectively.23-27 In addition, clinical and immunologic markers have been 47 
reported to be poor predictors of virologic suppression.16, 28-30 There is need to investigate 48 
efficient and cost-effective criteria for assessing treatment failure among HIV-1-infected 49 
children in resource-limited settings.  50 
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In Kenya, we have longitudinally followed up HIV-1 vertically-infected children, 51 
monitored CD4+T-cell counts quarterly and plasma VL biannually since 1999 and 2000, 52 
respectively, and reported the emergence of ARV-resistance mutations among the infecting 53 
HIV-1 strains together with evolutionary changes in the HIV-1 envelope gene.31,32  54 
 55 
OBJECTIVE 56 
To examine the response to ART, the proportion of treatment failure, and the profile 57 
of HIV-1 drug resistance-associated mutations among HIV-1 vertically-infected Kenyan 58 
children in order to determine appropriate marker(s) and frequency of monitoring children on 59 
ART in a resource-limited setting. 60 
 61 
STUDY DESIGN  62 
This was a retrospective study involving HIV-1 vertically-infected children from 63 
Nyumbani children’s home in Nairobi, Kenya. The study subjects have been described 64 
previously.31 Consent was obtained from the caretaker board of the orphanage, and the study 65 
proposal approved by the ethical committees of Kenya Government and Kanazawa 66 
University, Japan. Seventy-five children were included in this study. Their baseline 67 
characteristics are shown in Table 1. None of them had prior ART exposure. No death 68 
occurred during the follow-up.  69 
The ART initiation dates varied from March 1999 to October 2007. First-line ART 70 
consisted of two nucleoside reverse-transcriptase inhibitors (NRTI): mostly zidovudine and 71 
didanosine or lamivudine, and one non-nucleoside reverse-transcriptase inhibitor (NNRTI): 72 
nevirapine or efavirenz, as described in the WHO guidelines.14 In the current study, “ART 73 
success” was defined as plasma VL suppression to undetectable level or 1.5 log10 decrease 74 
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from baseline at 24 months after ART initiation, and “ART failure” was defined as two 75 
consecutive plasma VL above 5,000 copies/ml by the 24th month.  76 
Peripheral CD4+T-cell counts were determined using the FACSCOUNT (Becton-77 
Dickinson, Beiersdorf, Germany) quarterly and plasma HIV-1 RNA quantified biannually 78 
using the Amplicor HIV-1 Monitor kit version 1.5 (Roche Diagnostics, Alameda, CA) with 79 
detection limit of 400 copies/ml according to the manufacturer’s instructions. Absolute 80 
CD4+T-cell count was used instead of percentage CD4+T-cell count because it was the only 81 
available option during study period.  82 
HIV-1 RNA was extracted from plasma using SMITEST EX-R and D (Genome 83 
Science Laboratories, Fukushima, Japan) according to the manufacturer’s instructions. The 84 
HIV-1 reverse-transcriptase (RT) gene was amplified and population sequencing was done as 85 
previously described.31-34 The HIV-1 RT nucleotide sequences obtained from each child 86 
biannually during the first 24 months of ART were analyzed for previously-reported drug-87 
resistance mutations using the Stanford university HIV database 88 
(http://hivdb.stanford.edu/pages/algs/HIVdb.html/). The REGA HIV-1 subtyping tool 89 
(http://hivdb.stanford.edu/) was used to determine the HIV-1 subtype.  Pairwise comparisons 90 
were done in demographic, virologic, and immunologic parameters between treatment 91 
success and treatment failure groups using the student’s t-test.  92 
 93 
RESULTS  94 
Plasma VL changes before and after ART initiation is shown in Figure 1. Of the 75 95 
children studied, 53 (70.7%) suppressed plasma VL to undetectable level or more than 1.5 96 
log10 from baseline after 24 months of ART [Treatment success group]. Of the 53 treatment 97 
success children, 33 suppressed VL to undetectable level within 12 months [rapid responders] 98 
and 16 between 12-24 months (nine children within 18 months and seven within 24 months), 99 
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and four had detectable VL but suppressed their VL more than 1.5 log10 from baseline at 24 100 
months without any known HIV-1 RTI-resistance mutations [slow responders]. There was no 101 
significant difference in plasma VL at baseline between treatment success and failure groups 102 
(Table 1). 103 
The remaining 22 children (29.3%) did not suppress their VL more than 1.5 log10 104 
from baseline after 24 months of ART [Treatment failure group], though four of them 105 
suppressed plasma VL to undetectable level but their VL rebounded to above 5,000 copies/ml 106 
by the end of 24 months. In the 22 children, 21 subsequently developed HIV-1 RTI-107 
resistance mutations; cumulatively, seven children by six months, nine by 12 months, 13 by 108 
18 months, and 21 by 24 months. One female child failed therapy, but no known HIV-1 RTI-109 
resistance mutation was detected in this child after 24 months of ART (Table 2).  110 
Changes of CD4+T-cell counts before and after ART initiation are shown in Figure 2. 111 
CD4+T-cell counts increased in the first 12 months after ART initiation and kept the level 112 
thereafter irrespective of children’s ART outcome.  Although CD4+T-cell counts showed 113 
higher tendency in slow responder group than in rapid responder group, which was 114 
significant at baseline and after 24 months of ART (p<0.02 and p<0.05, respectively), there 115 
was no significant difference in CD4+T-cell counts at any time point between the treatment 116 
success and failure groups (data not shown).  117 
When the mean age at start of ART was compared between the treatment success and 118 
failure groups (8.3 years and 7.3 years, respectively), the difference was not statistically 119 
significant despite some trend showing younger age as being associated with treatment 120 
failure. In addition, mean age at start of ART was higher in rapid responders (9.1 years) than 121 
in slow responders (7.1 years), though the difference was not statistically significant (Table 122 
1).  123 
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HIV-1 genotypic analysis based on RT sequences showed that all the children were 124 
infected with non-B subtype HIV-1. There was no significant difference in the distribution of 125 
HIV-1 subtypes between treatment success and failure groups (Table 1). Treatment failure 126 
was higher in the nevirapine group (16/52, 30.8%) than in the efavirenz group (4/20, 20.0%), 127 
though the difference was not significant.  128 
The profiles of RTI-resistance mutations are summarized in Table 2. Of the 22 129 
children who failed treatment 21 developed mutations. None of the treatment success 130 
children had such mutations. Seven children developed drug-resistance mutations within 6 131 
months after initiating ART, two between 6 and 12 months, four between 12 and 18 months, 132 
and eight between 18 and 24 months. Of the 21 children, 20 had NRTI-resistance mutations, 133 
and 16 had NNRTI-resistance mutations. The common NRTI-resistance mutations were 134 
M184V, which appeared in 11 children, and thymidine analogue-associated mutations 135 
(TAMs): TAM 1 (M41L, L210W, and T215Y/F) and TAM 2 (D67N, K70R, and K219Q/E), 136 
which appeared in 13 and 13 children, respectively. Two of them had both TAM 1 and TAM 137 
2 profiles detected together. M184V appeared as the first primary NRTI-resistance mutation 138 
in six of the 20 children, with TAMs in five, TAMs without M184V in eight children, and 139 
T69N in one child. The most common NNRTI mutation was K103N, which appeared in 13 of 140 
the 21 children.  141 
The sequences obtained in this study were deposited at the Genebank under accession 142 
numbers: HQ586062-HQ586272. 143 
 144 
DISCUSSION  145 
In the current study, we followed up 75 HIV-1 vertically-infected children who were 146 
on first-line ART for at least 24 months. After 24 months of ART, the proportion of treatment 147 
success was 70.7% (53 children). During the two-year follow-up, the cumulative treatment 148 
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success rate was 29%, 44%, 56% and 71% at 6, 12, 18 and 24 months, respectively. It is of 149 
note that 20 “slow responders” were identified among the 53 treatment success children; their 150 
VL was suppressed to undetectable level or more than 1.5 log10 decrease from baseline 151 
between 12 and 24 months. These results suggest that HIV-1-infected children may need 152 
longer periods of ART to control virus replication comparing with adults.   153 
Twenty-two children (29.3%) failed therapy at 24 months after ART initiation. They 154 
maintained high VL: less than 1.5 log10 decrease from baseline, or rebounded after an initial 155 
good response during follow-up. The treatment failure rate in this study is within the range of 156 
previous reports from sub-Saharan Africa: 19.7% - 50%.23-27 Thus, ART failure appears to be 157 
more frequent in children than in adults, possibly due to the difference in the prevalence and 158 
profile of drug-resistance mutations in children compared with adults.35-38 In this study, at the 159 
time ART was initiated, ARV dosing was based on body weight and body surface area of 160 
children. Though children grow constantly hence it may be advisable to change dosing 161 
regularly,36,37 this was not possible in our settings. Furthermore, in this setting, all the 162 
children were carefully monitored by the staff of the children’s home and were therefore 163 
ART compliant. However, by mid-2000, ARVs were acquired through charity and 164 
prescription depended on drug availability. This might have affected ART compliance hence 165 
the higher failure rate. 166 
Of the 22 children who failed treatment, 21 developed drug-resistance mutations. 167 
Cumulatively, they were detected in 7, 9, 13 and 21 children at 6, 12, 18 and 24 months of 168 
ART, respectively. In seven children, TAMs emerged as first mutations without M184V, 169 
which is known to be associated with the use of lamivudine. Two of them had both TAM 1 170 
and TAM 2 profiles detected together. Despite being on a lamivudine-containing regimen, six 171 
children developed NRTI-resistance mutations devoid of M184V (Table 2). These findings 172 
may indicate a pathway different from what has been previously suggested.31 Nonetheless, 173 
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this is consistent with previous observations on the response to ART in children comparing 174 
with adults.38,39 Besides, one child failed therapy, but did not harbor HIV-1 strains with 175 
known RTI-resistance mutations. This may be due to unknown factors, such as low 176 
compliance, or other unknown drug-resistance mutations located outside of the RT region 177 
that was examined. The possible cause of treatment failure in this child is under investigation. 178 
The most observed NNRTI-resistance mutation was K103N, which is easily transmitted and 179 
persistent, and has become the most common mutation in patients failing first-line 180 
regimens.40  181 
The WHO recommends early initiation of ART for all HIV-1 vertically-infected 182 
children.41 To get a better clinical outcome, plasma VL and drug-resistance testing should be 183 
done before starting ART and as many times as possible during therapy to allow timely and 184 
optimized therapeutic change. However, most infected children reside in resource-limited 185 
countries where such monitoring is nonexistent.41 So far, clinical and immunological markers 186 
have been used for this purpose.42 However, there was no significant difference in the change 187 
of CD4+T-cell counts before and after ART initiation between the treatment success and 188 
failure groups. In addition, there was no difference in the plasma VL at baseline between the 189 
two groups. From these findings, it would be advisable that plasma viral load testing at 24 190 
months of ART be done to differentiate failing ART regimens. Additionally, drug-resistance 191 
testing, if affordable, at 24 months after initiating ART would also be helpful in choosing 192 
second-line regimens. 193 
 194 
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TABLE1: The characteristics of vertically-infected Kenyan children on ART 
Variable All Treatment Success (TS) Treatment failure 








     
Male, n (%)         41 (54.7)           28 (52.8)         19 (57.6)           9 (45.0)           13 (59.1) 
Female, n (%)         34 (45.3)           25 (47.2)         14 (42.4)         11 (55.0)             9 (40.9) 
Age at ART start (years) 
     
Mean (SD)        7.8 (3.9)           8.3 (4.1)         9.1 (4.3)        7.1 (3.3)           7.3 (3.1) 
Baseline viral load (log10copies/ml)      
Mean (SD)        5.1 (0.7)a           5.0 (0.8)         5.0 (0.8) c        4.9 (0.7)d           5.2 (0.5)d 
Baseline CD4+T-cell counts (/mm3)       
Mean (SD)       431 (310)b       445 (270)        376 (224) e*       584 (309) f*          469 (376)g 
HIV-1 subtype, n (%)      
A1         59 (78.7)           44 (83.0)         27 (81.8)         17 (85.0)           15 (68.2) 
C           3 (  4.0)             2 (3.8)           2 (6.1)           0 (  0   )             1 (4.55) 
D         12 (16.0)             7 (13.2)           4 (12.1)           3 (15.0)             5 (22.7) 
CRF02_AG           1 (  1.3)             0 (  0   )           0 (  0   )           0 (  0   )             1 (4.55) 
Drug Combinations, n (%) 
     
AZT/3TC/NVP         50 (66.7)           36 (67.9)         22 (66.7)         14 (70.0)           14 (63.6) 
AZT/ 3TC/ EFV         16 (21.3)           14 (26.4)           9 (27.3)           5 (25.0)             2 (  9.1) 
AZT/3TC/ABC           3 (  4.0)             1 (  1.9)           0 (  0   )           1 (  5.0)             2 (  9.1) 
AZT/ddI/EFV           3 (  4.0)             1 (  1.9)           1 (  3.0)           0 (  0   )             2 (  9.1) 
AZT/ddI/NVP           2 (  2.7)             0 (  0   )           0 (  0   )           0 (  0   )             2 (  9.1) 
d4T/3TC/EFV           1 (  1.3)             1 (  1.9)           1 (  3.0)           0 (  0   )             0 (  0   ) 
      
ART: antiretroviral therapy; AZT: zidovudine; 3TC: lamivudine; ddI: didanosine; ABC: abacavir; NVP: nevirapine; EFV: efavirenz; SD: standard deviation. † undetectable viral 




TABLE 2: Characteristics of children who failed therapy and time to emergence of first major RTI drug resistance-associated mutations 
 
ID GENDER AGE AT ART START REGIMEN 6 MONTHS 12 MONTHS 18 MONTHS 24 MONTHS 
38 M 8.6 AZT/3TC/NVP D67N D67N/K70R/L210W/K219E D67N/K70R/L210W/K219E D67N/K70R/L210W/K219E 
62 M 5.4 AZT/ddI/NVP D67N/K70R/G190A D67N/K70R/G190A / T215F/K219E  
D67N/K70R/G190A /T215F/ 
K219E /Y181C 
85 F 4.7 AZT/3TC/NVP D67N/M184V/K103N D67N/M184V/K103N   
103 M 3.2 AZT/3TC/NVP M184V/K103N M184V /L74V/K103N L74V/M184V/K103N L74V/M184V/K103N 
98 F 5.3 AZT/3TC/NVP M184V/K103N M184V/K103N M184V/K103N M184V/K103N 







36 M 7.4 AZT/3TC/ABC M184V/T215F/K103N M184V/T215F/K103N /G190A M184V/T215F/K103N /G190A M184V/T215F/K103N /G190A 
48 M 11.4 AZT/3TC/NVP NA M184V/K103N M184V/K103N M184V/K103N 
74 F 6.8 AZT/3TC/NVP NONE NONE NONE T69N /K103N 
73 F 6.7 AZT/3TC/NVP NONE NONE  K103N 
87 M 3.4 AZT/3TC/NVP NONE NONE  M41L 
80 M 5.5 AZT/3TC/NVP NONE NONE  M41L//A62V/T69P/K103N 
41 M 10.9 AZT/3TC/NVP NONE  M184V/K103N NA 
10 M 12.8 AZT/ddI/NVP NONE  M41L E44D/V118I 
122 M 11 AZT/3TC/NVP  M184V/K103N M184V/K103N M184V/K103N 
91 F 3.5 AZT/3TC/NVP   M184V/G190A M184V/G190A 
19 M 10 AZT/ddI/EFV   M184V/T215F/K103N/G190A M184V/T215F/K103N/G190A / M41L/D67N 
42 F 6.9 AZT/ddI/EFV    D67N/K70R 
33 F 7.6 AZT/3TC/EFV    K219Q/K101Q 
11 M 9.9 AZT/3TC/EFV    M41L//T215Y/K103N 
65 M 7.6 AZT/3TC/NVP    M41L/K103N/M184V 
7 F 11 AZT/3TC/ABC       NONE 
ART: antiretroviral therapy; RTI: reverse transcriptase inhibitor; AZT: zidovudine; 3TC: lamivudine; ddI: didanosine; ABC: abacavir; NVP: nevirapine; EFV: efavirenz. F: Female; M: Male; 







































































# p <0.05 
